Barry Hardy

CEO at Edelweiss Connect

Switzerland · BaselJoined December 2011


Dr. Barry Hardy is the Chief Executive Officer (CEO) at Edelweiss Connect where he is leading its team supporting the development of new integrating solutions in industrial safety assessment and the translation of research methods to industrial practice. Example recent commercial developments include the creation of the SaferWorldbyDesign collaboration platform (, and the development of the SaferSkin ( and EdelweissData products ( He is currently leading the development of new business partnerships and platforms with Wepredic ( and EU-ToxRisk (

He coordinated the OpenTox project in predictive toxicology and is currently President of the OpenTox Association, founded in 2015 as an international non-profit organisation promoting an open knowledge community approach to new methods in predictive toxicology and the 3Rs principles of the refinement, reduction and replacement of animal experiments.

Previously, he led the infrastructure development for the IMI EBiSC stem cell banking project, the eNanoMapper project developing solutions supporting nanotechnology safety assessment, OpenRiskNet infrastructure development supporting risk assessment, and knowledge infrastructure development for ACEnano, NanoCommons and EU-ToxRisk.

Dr. Hardy obtained his Ph.D. in 1990 from Syracuse University working in computational science. He was a National Research Fellow at the FDA Center for Biologics and Evaluation, a Hitchings-Elion Fellow at Oxford University and CEO of Virtual Environments International. He was a pioneer in the 1990s in the development of Web technology applied to virtual scientific communities and conferences. He has developed technology solutions for internet-based communications, tutor-supported e-learning, laboratory automation systems, and computational science and informatics. In recent years he has also been active in the field of knowledge management as applied to supporting innovation, communities of practice, and collaboration, with a particular focus on developing new evidence-based methods in predictive toxicology and safety assessment.

Research areas of interest (51)

  • Pharmaceutics
  • Computational Chemistry and Modelling
  • Micro- and Nanotechnology
  • Biological Sciences
  • Biostatistics, Epidemiology
  • and 46 more

Barry Hardy didn't publish any post yet

Barry Hardy didn't publish any Technology Call yet

Barry Hardy didn't publish any Technology Offer Offer yet

Barry Hardy didn't publish any Paper yet

Barry Hardy didn't publish any Event yet

Barry Hardy didn't publish any Job yet

Barry Hardy didn't publish any New and Article yet

Barry Hardy didn't publish any Education Resource yet

You are signed out

Join Innoget to connect with Barry Hardy and thousands
of innovation-driven professionals and organizations